AbbVie Named Top High-Yield Dividend in Post-Humira Landscape as New Competitor Enters $11B Aesthetics Market
ABBV•Emerging biotech Conexeu Sciences finished its P.R.O.O.F preclinical study for CXU, targeting an $11 billion medical-aesthetics injectable gap created by the $79 billion GLP-1 weight-loss boom and positioning itself against incumbents such as AbbVie. AbbVie also appears among three high-yield dividend picks now that it has moved past Humira's patent expiration.
1. Conexeu's CXU Preclinical Milestone and Competitive Dynamics
Conexeu Sciences completed the 12-month P.R.O.O.F preclinical study for its CXU platform, aiming to address facial and body volume loss created by GLP-1 weight-loss therapies. The company targets an $11 billion medical-aesthetics injectable market gap and positions itself against established injectables providers, including AbbVie, with a predicate-based 510(k) filing planned for Q1 2027.
2. AbbVie's Dividend Position and Post-Humira Transition
AbbVie has transitioned beyond Humira's patent expiration and maintains a dividend yield above 4%, earning its place among top high-yield stocks for long-term investors. The company's diversified portfolio and robust cash flow support sustained dividend growth, reinforcing its appeal for income-focused shareholders.
